Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)
Clinical trial NCT04880434 · COMPLETED
Trial details
- NCT number
- NCT04880434
- Sponsor
- Kite, A Gilead Company
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-23
- Primary completion
- 2025-06-17
- Enrollment
- 95
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.